Table 1.
Patient characteristics
| Characteristics | Axi-cel | Tisa-cel | All | |
|---|---|---|---|---|
| Number of patients | 43 (71.7%) | 17 (28.3%) | 60 (100%) | |
| Median age, years old (range) - Nº of patients ≤ 60 years old - Nº of patients > 60 years old |
61 (19–78) 20 (33.3%) 23 (53.4%) |
71 (45–85) 4 (23.5%) 13 (76.4%) |
63 (19–85) 24 (40%) 36 (60%) |
|
| Gender - Male - Female |
35 (81.4%) 8 (18.6%) |
7 (41.2%) 10 (58.8%) |
42 (70%) 18 (30%) |
|
| Performance status <1 | 36 (83.7%) | 16 (94.1%) | 52 (86.7%) | |
| Underlying disease - De novo DLBCL - Transformed DLBCL Histological subtypes - DLBCL, subtype Germinal Center B-cell - DLBCL, subtype Non-Germinal Center B-cell - High grade lymphoma B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements - Other subtypes |
24 (55.8%) 19 (44.2%) 19 (44.2%) 14 (32.5%) 5 (11.6%) 5 (11.6%) |
11 (64.7%) 6 (35.3%) 6 (35.3%) 10 (58.8%) 1 (5.9%) 0 (0%) |
35 (58.3%) 25 (41.7%) 25 (41.7%) 24 (40%) 6 (10%) 5 (8.3%) |
|
| Nº patients with calculable stage* - Stage III or IV |
38 35 (92.1%) |
14 10 (71.4%) |
52 45 (86.5%) |
|
| Elevated LDH | 24 (63.1%) | 6 (35.3%) | 30 (50%) | |
| Prior autologous transplant | 9 (20.9%) | 3 (17.6%) | 12 (20%) | |
| Prior allogeneic transplant | 5 (11.6%) | 0 (0%) | 5 (8.3%) | |
| Lymphodepleting regimen - FluCy - Bendamustine |
43 (100%) - |
14 (82.3%) 3 (17.6%) |
- |
|
| Comorbidities | Axi-cel (n=43) |
Tisa-cel (n=17) |
All patients (n=60) |
Calculable HCT-CI (n=15) |
| - Arrhythmia - Cardiac - Inflammatory bowel disease - Diabetes Mellitus ◦ Diabetes Mellitus with end organ damage - Cerebrovascular disease - Psychiatric disturbance - Hepatic impairment, mild - Obesity - Infection - Rheumatologic disorders - Peptic ulcer - Moderate/severe renal abnormalities - Chronic pulmonary disease1 - Moderate pulmonary1 - Prior solid tumor - Any solid tumor during the last 5 years - Heart valve disease - Severe pulmonary1 - Moderate/severe hepatic impairment |
5 (11.6%) 5 (11.6%) 0 (0%) 5 (11.6%) 2 (4.6%) 1 (2.3%) 6 (13.9%) 8 (18.6%) 7 (16.3%) 7 (16.3%) 4 (9.3%) 3 (7%) 0 (0%) 4 (9.3%) 2 (4.6%) 3 (7%) 2 (4.6%) 6 (13.9%) 4 (9.3%) 1 (2.3%) |
4 (23.5%) 3 (17.6%) 1 (5.9%) 1 (5.9%) 0 (0%) 1 (5.9%) 2 (11.8%) 2 (11.8%) 1 (5.9%) 2 (11.8%) 2 (11.8%) 1 (5.9%) 0 (0%) 0 (0%) 2 (11.8%) 3 (17.6%) 1 (5.9%) 3 (17.6%) 0 (0%) 0 (0%) |
9 (15%) 8 (13.3%) 1 (1.6%) 6 (10%) 2 (3.3%) 2 (3.3%) 8 (13.3%) 10 (16.6%) 8 (13.3%) 9 (15%) 6 (10%) 4 (6.6%) 0 (0%) 4 (6.6%) 4 (6.6%) 6 (10%) 3 (5%) 9 (15%) 4 (6.6%) 1 (1.6%) |
3 (20%) 2 (13.3%) 0 (0%) 3 (20%) 1 (6.6%) 1 (6.6%) 0 (0%) 3 (20%) 3 (20%) 1 (6.6%) 2 (13.3%) 1 (6.6%) 0 (0%) 2 (13.3%) 4 (26.6%) 0 (0%) 0 (0%) 2 (13.3%) 4 (26.6%) 0 (0%) |
1
Diagnosis based on clinical symptoms. DLBCL: Diffuse large B-cell lymphoma, LDH: Lactate dehydrogenase.